MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2015.129221

Медицинская библиотека · Haematologica · 2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.

Gugliotta Gabriele, Castagnetti Fausto, Breccia Massimo, Levato Luciano, D'Adda Mariella, Stagno Fabio, Tiribelli Mario, Salvucci Marzia, Fava Carmen, Martino Bruno, Cedrone Michele, Bocchia Monica, Trabacchi Elena, Cavazzini Francesco, Usala Emilio, Russo Rossi Antonella, Bochicchio Maria Teresa, Soverini Simona, Alimena Giuliana, Cavo Michele, Pane Fabrizio, Martinelli Giovanni, Saglio Giuseppe, Baccarani Michele, Rosti Gianantonio, GIMEMA CML Working Party

Клиническое исследование II фазыСравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib versus imatinib (ENESTnd). Apart from this registration study, very few data are currently available on first-line nilotinib treatment. We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with chronic-phase chronic myeloid leukemia. Six-year overall survival and progression-free survival rates were 96%, with one death after progression to blast phase. At 6 years, 75% of the patients were still on nilotinib. The cumulative incidence of major molecular response was 98%; only one patient had a confirmed loss of major molecular response. The cumulative incidence of deep molecular response (MR 4.0) was 76%. Deep molecular response was stable (≥ 2 years) in 34% of these patients. Cardiovascular adverse events, mainly due to arterial thrombosis, occurred in 11/73 patients (15%), after 24 to 76 months of therapy. They were more frequent in elderly patients, and in those with baseline cardiovascular risk factors. None was fatal, although there was a relevant morbidity. This is the study with the longest follow-up of a high dose of nilotinib (400 mg twice daily): it highlights the high efficacy and the cardiovascular toxicity of the drug (CTG.NCT.00481052).

Для цитирования: Gugliotta Gabriele, Castagnetti Fausto, Breccia Massimo, Levato Luciano, D'Adda Mariella, Stagno Fabio, Tiribelli Mario, Salvucci Marzia, Fava Carmen, Martino Bruno, Cedrone Michele, Bocchia Monica, Trabacchi Elena, Cavazzini Francesco, Usala Emilio, Russo Rossi Antonella, Bochicchio Maria Teresa, Soverini Simona, Alimena Giuliana, Cavo Michele, Pane Fabrizio, Martinelli Giovanni, Saglio Giuseppe, Baccarani Michele, Rosti Gianantonio, GIMEMA CML Working Party. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.. Haematologica. 2015. DOI: 10.3324/haematol.2015.129221.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.